logo
RSA Announces New RSA Governance & Lifecycle ISPM Capabilities at EIC 2025

RSA Announces New RSA Governance & Lifecycle ISPM Capabilities at EIC 2025

Business Wire07-05-2025
BERLIN--(BUSINESS WIRE)--RSA, the security-first identity leader, today announced new Identity Security Posture Management (ISPM) capabilities that will help enterprises proactively find and resolve security risks across hybrid and cloud environments. Built into the RSA ® Governance & Lifecycle identity governance and administration (IGA) solution, the new ISPM features address critical cybersecurity risks that result from cloud computing, remote work, and the growth of human and non-human identities.
Combined with newly released RSA Governance & Lifecycle IGA enhancements, RSA ISPM innovations help organizations proactively reduce their identity attack surface. New AI-powered dashboards deliver proactive and actionable insights into policy violations, excessive entitlements, orphaned accounts, and other critical risks that can weaken security and compliance. RSA solutions don't stop at identifying risks: they go further by recommending specific actions to resolve issues, helping organizations move quickly from insight to resolution.
Increasingly complex IT environments have made it impossible for organizations to gain a comprehensive understanding of their identity posture using traditional approaches to identity and access management, leaving them vulnerable to attacks, compliance fines, and other risks. To adapt to this evolving threat landscape, organizations are turning to ISPM, a new cybersecurity framework that complements traditional IGA functions by stressing comprehensive visibility, continuous risk assessment, and automated remediation of identity-related vulnerabilities.
RSA Governance & Lifecycle provides the ISPM capabilities enterprises need to gain comprehensive visibility into their identity ecosystem. Its advanced dashboards, powered by AI, analyze identity data to proactively uncover vulnerabilities, prioritize risks, and deliver clear, actionable insights for admins, business leaders, and executives. The new RSA Governance & Lifecycle ISPM capabilities will be generally available in Q3 2025.
'Reactive identity security capabilities simply aren't sufficient for today's threats, which demand solutions that can proactively find, prioritize, and resolve identity risks,' said RSA CEO Rohit Ghai. 'Government agencies, banks, healthcare, energy, and other security-first organizations need a unified identity platform—including strong access security, enterprise-grade passwordless authentication, governance, and lifecycle operating in an ISPM framework—to stop cyberattacks, stay in compliance, and accelerate productivity.'
'For identity teams overwhelmed by data, the new AI-powered dashboards from RSA provide the proactive information they need to prioritize actions and enhance their security,' said RSA Chief Product and Technology Officer Jim Taylor. 'With more threats, higher compliance expectations, and shrinking cybersecurity budgets, the new RSA Governance & Lifecycle ISPM capabilities can help organizations do more—and more effectively—with less.'
'RSA Governance & Lifecycle provides organizations with the tools, visibility, and insights they need to mature their cybersecurity stance, proactively resolve risks, and fulfill audit requirements,' said Alaa Abdulnabi, RSA SVP and General Manager, International. 'These innovations ensure that high-security organizations can stay ahead of cybersecurity threats and operational challenges.'
The new RSA Governance & Lifecycle ISPM capabilities and other solution enhancements announced at EIC 2025 offer key benefits for enterprises, including:
Unparalleled visibility: Advanced dashboards offer a comprehensive view of identity risk across your entire environment, enabling organizations to take proactive measures to secure resources, reduce their attack surface, and prevent breaches before they happen.
Actionable insights for everyone: Dashboards visualize complex data for admins, business leaders, and executives to coordinate and prioritize action.
Easier, continuous compliance: New RSA Governance & Lifecycle ISPM capabilities make it easy to surface the evidence auditors need, highlight areas that require attention, and reveal opportunities to reduce risk—all while maturing Zero Trust architecture and aiding with GDPR, SOX, ISO 27001, SOC 2, and other compliance initiatives.
RSA Governance & Lifecycle provides these capabilities in a solution recognized for its flexible deployment options, comprehensive visibility, and engaging gamification features that drive a culture of compliance and boost user satisfaction. These capabilities make RSA Governance & Lifecycle a powerful tool for enterprises looking to enhance their ISPM strategy, while simplifying governance and lifecycle management.
EIC attendees can meet RSA at Booth 7 to preview these new innovations. They are also invited to join RSA Field CTO International Ingo Schubert at the following presentations:
Clear Skies: What If Suddenly There Is No Cloud? Join Ingo on May 8 at 12:25 pm CEST in B 09 to learn how organizations can build resilience, prevent threats, and meet DORA and NIS2 requirements even if cloud-based multi-factor authentication goes offline.
How to Secure Data in the Cloud - Is Encryption Enough? Join Ingo for a panel conversation on May 8 at 12:45 pm CEST in B 09 to learn how encryption, Zero Trust architecture, and AI-driven threat detection can secure data in the cloud.
Have questions or want to speak with someone directly? Contact us and RSA representatives will contact you directly.
About RSA
RSA provides mission-critical cybersecurity solutions that protect the world's most security-sensitive organizations. The RSA Unified Identity Platform provides true passwordless identity security, risk-based access, automated identity intelligence, and comprehensive identity governance across cloud, hybrid, and on-premises environments. More than 9,000 high-security organizations trust RSA to manage more than 60 million identities, detect threats, secure access, and enable compliance. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

Business Wire

timea minute ago

  • Business Wire

Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

FREMONT, Calif.--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments. 'Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions,' stated Tivic CEO, Jennifer Ernst. 'While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome.' About Entolimod Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA's Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS. Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome. About Tivic Tivic's dual platform strategy utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late-stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors,' as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

The Toro Company to Announce Fiscal 2025 Third Quarter Results
The Toro Company to Announce Fiscal 2025 Third Quarter Results

Business Wire

timea minute ago

  • Business Wire

The Toro Company to Announce Fiscal 2025 Third Quarter Results

BLOOMINGTON, Minn.--(BUSINESS WIRE)--The Toro Company (NYSE: TTC), a leading global provider of solutions for the outdoor environment, today announced that it will release its fiscal 2025 third quarter results on Thursday, September 4, at approximately 7:30 a.m. CT. The full text of The Toro Company's earnings release will be available at that time at The company will also hold an earnings conference call at 10 a.m. CT that day. A live, listen-only webcast of the earnings conference call will be available at Visitors are encouraged to go to the website in advance of the call to register, and download and install any necessary audio software. A replay will be available on the website shortly following the call. About The Toro Company The Toro Company (NYSE: TTC) is a leading global provider of solutions for the outdoor environment including turf and landscape maintenance, snow and ice management, underground utility construction, rental and specialty construction, and irrigation and outdoor lighting solutions. With net sales of $4.6 billion in fiscal 2024, The Toro Company's global presence extends to more than 125 countries through a family of brands that includes Toro, Ditch Witch, Exmark, Spartan, BOSS, Ventrac, American Augers, Subsite, HammerHead, Radius, Perrot, Hayter, Unique Lighting Systems, Irritrol, and Lawn-Boy. Through constant innovation and caring relationships built on trust and integrity, The Toro Company and its family of brands have built a legacy of excellence by helping customers work on golf courses, sports fields, construction sites, public green spaces, commercial and residential properties and agricultural operations. For more information, visit

Guess?, Inc. to Release Second Quarter Fiscal 2026 Financial Results
Guess?, Inc. to Release Second Quarter Fiscal 2026 Financial Results

Business Wire

timea minute ago

  • Business Wire

Guess?, Inc. to Release Second Quarter Fiscal 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Guess?, Inc. (NYSE: GES) will release its financial results for the second quarter of fiscal year 2026, which ended August 2, 2025, on Wednesday, August 27, 2025. The financial results will be accessible at via the 'Investor Relations' link. In light of the pending take-private transaction announced separately today, Guess? will not host a conference call in connection with its quarterly results. Guess?, Inc. designs, markets, distributes and licenses a lifestyle collection of contemporary apparel, denim, handbags, watches, eyewear, footwear and other related consumer products. Guess? products are distributed through branded Guess? stores as well as better department and specialty stores around the world. At May 3, 2025, the Company directly operated 1,074 retail stores in Europe, the Americas and Asia. The Company's partners and distributors operated 527 additional retail stores worldwide. At May 3, 2025, the Company and its partners and distributors operated in approximately 100 countries worldwide. For more information about the Company, please visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store